We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
A Randomized Study of Interferon α-2b Versus No Treatment as Consolidation After High Dose Therapy and Autologous Stem Cell Transplantation for Patients With Relapsed Lymphoma.
- Authors
Bosly, André; Grigg, Andrew; Holte, Harald; Gisselbrecht, Christian; Radford, John; Rossi, Andrea; Lopez‐Guillermo, Armando; Trneny, Marek; Sebban, Catherine; Hagberg, Hans; Leal da Costa, Fernando; Colombat, Philippe; Bron, Dominique; Coiffier, Bertrand
- Abstract
Background: Patients with lymphoma who have experienced a first relapse or progression and have disease deemed sensitive to salvage chemotherapy nevertheless have a high likelihood of having a second relapse. To decrease the likelihood of a second relapse after high-dose therapy (HDT) and autologous stem cell transplantation (ASCT), interferon (IFN) -2b was given in a prospective randomized international trial. Methods: In this trial, 221 patients with varying histologic diagnoses (8 small lymphocytic, 37 follicular, 9 mantle, 90 diffuse large B-cell,20peripheral T-cell,3high-grade B-cell non-Hodgkin lymphoma, and 54Hodgkinlymphoma)wererandomlyassigned to receivenofurthertreatment(armA:117patients) or IFN -2b, 3MUthree times weekly, for 18 months (arm B: 104 patients). Results: In arm B, 21 patients (20%) did not receive IFN -2b because of early progressionor absence of hematologic recovery, 29patients(28%)completedthe18monthsoftreatment, and54 patients (52%) interrupted treatment because of progression (23%) or toxicity (29%). Event-free survival and overall survival were not different between the two arms on an intent-to-treat analysis and also if analysis was restricted to patients who were aliveandhadnot experienced disease progression threemonths after transplantation. The study was not sufficiently powered to evaluate effects in histologic subtypes. Conclusion: In this trial, post-autograft IFN -2b did not improve outcomesin a heterogeneous group of patients withlymphoma.
- Subjects
SALVAGE therapy; HEMATOPOIETIC stem cell transplantation; INTERFERONS; LYMPHOMAS; STATISTICAL sampling; SURVIVAL analysis (Biometry); RANDOMIZED controlled trials; DISEASE progression
- Publication
Oncologist, 2013, Vol 18, Issue 11, p1189
- ISSN
1083-7159
- Publication type
Article
- DOI
10.1634/theoncologist.2013-0223